Improved microRNA quantification in total RNA from clinical samples

被引:85
作者
Andreasen, Ditte [1 ]
Fog, Jacob U. [1 ]
Biggs, William [1 ]
Salomon, Jesper [1 ]
Dahslveen, Ina K. [1 ]
Baker, Adam [1 ]
Mouritzen, Peter [1 ]
机构
[1] Exiqon AS, DK-2950 Vedbaek, Denmark
关键词
microRNA; qPCR; Locked Nucleic Acid; Biomarker; Plasma; FFPE; CIRCULATING MICRORNAS; GENE-EXPRESSION; BIOMARKERS; CANCER;
D O I
10.1016/j.ymeth.2010.01.006
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
microRNAs are small regulatory RNAs that are currently emerging as new biomarkers for cancer and other diseases. In order for biomarkers to be useful in clinical settings, they should be accurately and reliably detected in clinical samples such as formalin fixed paraffin embedded (FFPE) sections and blood serum or plasma. These types of samples represent a challenge in terms of microRNA quantification. A newly developed method for microRNA qPCR using Locked Nucleic Acid (LNA (TM))-enhanced primers enables accurate and reproducible quantification of microRNAs in scarce clinical samples. Here we show that LNA (TM)-based microRNA qPCR enables biomarker screening using very low amounts of total RNA from FFPE samples and the results are compared to microarray analysis data. We also present evidence that the addition of a small carrier RNA prior to total RNA extraction, improves microRNA quantification in blood plasma and laser capture microdissected (LCM) sections of FFPE samples. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:S6 / S9
页数:4
相关论文
共 13 条
  • [1] Expression profiling of microRNA using real-time quantitative PCR, how to use it and what is available
    Benes, Vladimir
    Castoldi, Mirco
    [J]. METHODS, 2010, 50 (04) : 244 - 249
  • [2] The Therapeutic Potential of microRNAs in Nervous System Damage, Degeneration, and Repair
    Hutchison, Emmette R.
    Okun, Eitan
    Mattson, Mark P.
    [J]. NEUROMOLECULAR MEDICINE, 2009, 11 (03) : 153 - 161
  • [3] Lewis F, 2001, J PATHOL, V195, P66, DOI 10.1002/1096-9896(200109)195:1<66::AID-PATH921>3.0.CO
  • [4] 2-F
  • [5] Liu AH, 2009, INT J CLIN EXP PATHO, V2, P519
  • [6] Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples
    Masuda, N
    Ohnishi, T
    Kawamoto, S
    Monden, M
    Okubo, K
    [J]. NUCLEIC ACIDS RESEARCH, 1999, 27 (22) : 4436 - 4443
  • [7] Meola Nicola, 2009, Pathogenetics, V2, P7, DOI 10.1186/1755-8417-2-7
  • [8] MicroRNAs in clinical oncology: at the crossroads between promises and problems
    Metias, S. M.
    Lianidou, E.
    Yousef, G. M.
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2009, 62 (09) : 771 - 776
  • [9] Circulating microRNAs as stable blood-based markers for cancer detection
    Mitchell, Patrick S.
    Parkin, Rachael K.
    Kroh, Evan M.
    Fritz, Brian R.
    Wyman, Stacia K.
    Pogosova-Agadjanyan, Era L.
    Peterson, Amelia
    Noteboom, Jennifer
    O'Briant, Kathy C.
    Allen, April
    Lin, Daniel W.
    Urban, Nicole
    Drescher, Charles W.
    Knudsen, Beatrice S.
    Stirewalt, Derek L.
    Gentleman, Robert
    Vessella, Robert L.
    Nelson, Peter S.
    Martin, Daniel B.
    Tewari, Muneesh
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (30) : 10513 - 10518
  • [10] (micro)genomic medicine microRNAs as therapeutics and biomarkers
    Saunders, Matthew A.
    Lim, Lee P.
    [J]. RNA BIOLOGY, 2009, 6 (03) : 324 - 328